Critical Path Institute

FDA, IBM partner on the secure exchange of clinical data

Monday, January 23, 2017

Secure storage and controlled access to sensitive patient data are critical aspects of the clinical trial process. Investigators may need to access huge data sets shared across national and international sites. The amount and sheer number of types of data is rapidly increasing as the use of mobile and wearable devices and the querying of genomic databases are incorporated into trial design.

[Read More]

MSOAC launches database for MS clinical trial data

Tuesday, April 26, 2016

A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators. This is just one of the tools generated through the Multiple Sclerosis Outcome Assessments Consortium (MSOAC), a global effort launched by the National MS Society and Critical Path Institute (C-Path). MSOAC is striving to develop an outcomes measure that addresses the critical need for a more sensitive way to detect the benefit of potential treatments that slow or reverse progressive disability in people with MS.

[Read More]

CDISC, TransCelerate release new standards for diabetes, cardiovascular disease

Wednesday, November 26, 2014

The Clinical Data Interchange Standards Consortium (CDISC), a global nonprofit, and King of Prussia, Pa.-based nonprofit TransCelerate BioPharma have made available therapeutic area standards for diabetes and cardiovascular (CV) disease areas through the Coalition for Accelerating Standards and Therapies (CFAST), a joint initiative of CDISC and the Critical Path Institute (C-Path).

[Read More]

Critical Path Institute receives grant for tuberculosis treatments

Wednesday, February 12, 2014

The Critical Path Institute, an independent nonprofit that catalyzes innovative ideas to accelerate the speed of drug and medical product development, has received a three-year grant from the Bill & Melinda Gates Foundation. The grant will be used to develop quantitative mathematical models to optimize the design of clinical trials and tackle challenges facing the development of effective tuberculosis (TB) treatments.  

[Read More]

C-Path names Martha Brumfield as CEO

Tuesday, February 26, 2013

The board of directors of the Critical Path Institute (C-Path), an independent, nonprofit organization, have named Martha Brumfield, Ph.D., as interim president and CEO. Brumfield, C-Path’s former director of international and regulatory programs, will take over immediately for Carolyn Compton, M.D., Ph.D. who will be assuming a new position at Arizona State University (ASU).

[Read More]